redasertib

Redasertib (S-301409) is an investigational small molecule Toll-like receptor 7 (TLR7) agonist developed by Shionogi for the treatment of allergic rhinitis. By selectively activating TLR7, the compound acts as an immunomodulator designed to shift the immune response from a Th2-biased allergic profile toward a Th1-biased response, thereby potentially providing long-term relief from allergic symptoms. The drug has been evaluated in Phase I clinical trials, including the study QSC301409 conducted by Quotient Sciences, to assess its safety, tolerability, and pharmacokinetics in healthy volunteers and individuals with allergies.